YouTube Facebook LinkedIn Google+ Twitter Xingrss  

A Look at Gene Patents and Myriad


March 20, 2013 | On April 15, the Supreme Court will again hear a case against Myriad Genetics' gene patents. Though the legal debate is unlikely to end there, the decision could have implications for personalized medicine. Even the researcher who was originally responsible for the Myriad patent of BRCA2 has changed his tune. “Now, these patents are standing in the way of progress in personalized medicine,” says Sean Tavtigian. PBS
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.